UNSPSC 51111784: Atezolizumab

Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).

UNSPSC 51111784 Atezolizumab, a Commodity code, shows minimal recent state and local procurement activity aligned with the pharmaceutical product itself. The recent opportunities block contains no active solicitations for atezolizumab or other branded or generic cancer immunotherapy drugs. Instead, the tagged records span unrelated procurement categories: administrative relocation notices, naloxone and drug deactivation systems for emergency response, basic and advanced life support pharmaceuticals for fire department EMS programs, forensic drug reference standards for laboratory analysis, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, vendor networking events and forums, and healthcare services procurement. None of these opportunities involve atezolizumab procurement. The one record that directly references pharmaceutical acquisition—the MMCAP cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—targets generic drugs and over-the-counter items distributed through authorized wholesalers, not specialty biologics or branded cancer therapeutics.

State and local governments do procure specialized pharmaceuticals, including oncology agents, through health departments, county health systems, hospital purchasing cooperatives, and Medicaid agencies, but the UNSPSC code 51111784 shows no relevant recent activity in the current opportunities dataset. The mismatch between the code's nominal scope and the actual records suggests either misclassification in the source data or absence of active demand for this specific product in the recent state and local market. Firms pursuing atezolizumab sales to state and local buyers should monitor cooperative purchasing vehicles such as MMCAP and regional health purchasing consortia, and track specialty pharmaceutical procurement through county health authorities and state Medicaid managed-care contracts, but should not rely on this code as a reliable demand signal at present.